Do we need more drugs for chronic myeloid leukemia?

Chronic myeloid leukemia stem cells in the era of targeted therapies: resistance, persistence and long-term dormancy

(2015) Jean-Claude Chomel et al.   Oncotarget

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

(2015) Ophelie Cassuto et al.   Oncotarget

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias

(2014) L. Dubrovsky et al.   BLOOD

Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations

(2014) E. Traer et al.   BLOOD

Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

(2014) Francesca Pellicano et al.   STEM CELLS

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

TWIST it but don't spin it

(2013) J. F. Apperley   BLOOD

Autocrine TNF-  production supports CML stem and progenitor cell survival and enhances their proliferation

(2013) P. Gallipoli et al.   BLOOD

Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

(2013) E. Bolton-Gillespie et al.   BLOOD

JAK of all trades: JAK2-STAT5 as novel therapeutic targets in BCR-ABL1+ chronic myeloid leukemia

(2013) W. Warsch et al.   BLOOD

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

(2013)   BLOOD

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt- -catenin signaling

(2013) B. Zhang et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Safety and efficacy of pulsed imatinib with or without G-CSFversuscontinuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up

(2013) Paolo Gallipoli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Regulation of c-Myc Ubiquitination Controls Chronic Myelogenous Leukemia Initiation and Progression

(2013) Linsey Reavie et al.   CANCER CELL

Ablation of Fbxw7 Eliminates Leukemia-Initiating Cells by Preventing Quiescence

(2013) Shoichiro Takeishi et al.   CANCER CELL

Advances in Immunotherapy of Chronic Myeloid Leukemia CML

(2013) Stefanie Erika Held et al.   CURRENT CANCER DRUG TARGETS

Autophagy in Chronic Myeloid Leukaemia: Stem Cell Survival and Implication in Therapy

(2013) Gudmundur Helgason et al.   CURRENT CANCER DRUG TARGETS

Wnt signaling in stem and cancer stem cells

(2013) Jane D Holland et al.   CURRENT OPINION IN CELL BIOLOGY

Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice

(2013) L. Soucek et al.   GENES & DEVELOPMENT

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells

(2013) Paolo Neviani et al.   JOURNAL OF CLINICAL INVESTIGATION

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting Primitive Chronic Myeloid Leukemia Cells by Effective Inhibition of a New AHI-1–BCR-ABL–JAK2 Complex

(2013) Min Chen et al.   JNCI-Journal of the National Cancer Institute

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

(2013) J.E. Cortes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy

(2013) L Qin et al.   Blood Cancer Journal

Expression of BCR/ABL p210 from a Knockin Allele Enhances Bone Marrow Engraftment without Inducing Neoplasia

(2013) Samantha B. Foley et al.   Cell Reports

Cancer Vaccines and T Cell Therapy

(2012) Katayoun Rezvani et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management

(2012) S. Branford et al.   BLOOD

Targeting of GSK3  promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells

(2012) G. Reddiconto et al.   BLOOD

Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response

(2012) L. Legros et al.   BLOOD

Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML

(2012) A. Agarwal et al.   BLOOD

Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors

(2012) M. Nieborowska-Skorska et al.   BLOOD

BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships

(2012) J. S. Khorashad et al.   BLOOD

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

(2012) Ling Li et al.   CANCER CELL

Altered Microenvironmental Regulation of Leukemic and Normal Stem Cells in Chronic Myelogenous Leukemia

(2012) Bin Zhang et al.   CANCER CELL

p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice

(2012) Talía Velasco-Hernández et al.   CELL CYCLE

Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

(2012) Florian H. Heidel et al.   Cell Stem Cell

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Re-emergence of interferon-α in the treatment of chronic myeloid leukemia

(2012) M Talpaz et al.   LEUKEMIA

Scd1 Plays a Tumor-Suppressive Role in Survival of Leukemia Stem Cells and the Development of Chronic Myeloid Leukemia

(2012) H. Zhang et al.   MOLECULAR AND CELLULAR BIOLOGY

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML

(2012) Georg E Winter et al.   Nature Chemical Biology

BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia

(2012) Oliver Hantschel et al.   Nature Chemical Biology

The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells

(2012) Haojian Zhang et al.   NATURE GENETICS

The long-term clinical implications of clonal chromosomal abnormalities in newly diagnosed chronic phase chronic myeloid leukemia patients treated with imatinib mesylate

(2012) Sung-Eun Lee et al.   Cancer Genetics

Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia

(2011) Jungwon Huh et al.   ANNALS OF HEMATOLOGY

TNF  facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms

(2011) A. G. Fleischman et al.   BLOOD

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population

(2011) F. Efficace et al.   BLOOD

BCR-ABL suppresses autophagy through ATF5-mediated regulation of mTOR transcription

(2011) Z. Sheng et al.   BLOOD

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival

(2011) A. Hamilton et al.   BLOOD

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

(2011) S. Chu et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

(2011) A. Kumari et al.   BLOOD

Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML

(2011) G. V. Helgason et al.   BLOOD

Restricted access to second generation tyrosine kinase inhibitors in the UK could result in suboptimal treatment for almost half of chronic myeloid leukaemia patients: results from a West of Scotland and Lothian population study

(2011) Paolo Gallipoli et al.   BRITISH JOURNAL OF HAEMATOLOGY

Loss or Inhibition of Stromal-Derived PlGF Prolongs Survival of Mice with Imatinib-Resistant Bcr-Abl1+ Leukemia

(2011) Thomas Schmidt et al.   CANCER CELL

Antigens in chronic myeloid leukemia: implications for vaccine development

(2011) Michal Šmahel   CANCER IMMUNOLOGY IMMUNOTHERAPY

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

The CML stem cell: Evolution of the progenitor

(2011) Scott A. Stuart et al.   CELL CYCLE

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks: Figure 1.

(2011) Francesca Pellicano et al.   JOURNAL OF EXPERIMENTAL MEDICINE

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

(2011) Christian Hurtz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein

(2011) A S M Yong et al.   LEUKEMIA

A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases

(2011) V Grossmann et al.   LEUKEMIA

Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib

(2011) E Weisberg et al.   LEUKEMIA

Hydroxychloroquine for chronic myeloid leukemia: complete cure on the horizon?

(2011) Arunima Mukhopadhyay et al.   Expert Review of Hematology

Wnt/Ca2+/NFAT Signaling Maintains Survival of Ph+ Leukemia Cells upon Inhibition of Bcr-Abl

(2010) Mark A. Gregory et al.   CANCER CELL

Rapid clonal shifts in response to kinase inhibitor therapy in chronic myelogenous leukemia are identified by quantitation mutation assays

(2010) C. Cameron Yin et al.   CANCER SCIENCE

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate

(2010) B. D. Smith et al.   CLINICAL CANCER RESEARCH

Expression of a Src Family Kinase in Chronic Myelogenous Leukemia Cells Induces Resistance to Imatinib in a Kinase-dependent Manner

(2010) Teodora Pene-Dumitrescu et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Chronic myeloid leukemia: mechanisms of blastic transformation

(2010) Danilo Perrotti et al.   JOURNAL OF CLINICAL INVESTIGATION

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

(2010) Amie S. Corbin et al.   JOURNAL OF CLINICAL INVESTIGATION

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

(2010) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

TGF-β–FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

(2010) Kazuhito Naka et al.   NATURE

Complete molecular response in CML after p210 BCR–ABL1-derived peptide vaccination

(2010) Monica Bocchia et al.   Nature Reviews Clinical Oncology

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study

(2009) L. Noens et al.   BLOOD

SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations

(2009) D. Nowak et al.   BLOOD

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Targeting autophagy potentiates tyrosine kinase inhibitor–induced cell death in Philadelphia chromosome–positive cells, including primary CML stem cells

(2009) Cristian Bellodi et al.   JOURNAL OF CLINICAL INVESTIGATION

Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment

(2009) C Haferlach et al.   LEUKEMIA

A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response

(2009) M W Drummond et al.   LEUKEMIA

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

(2009) A Hochhaus et al.   LEUKEMIA

Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors

(2009) S. Grosso et al.   MOLECULAR CANCER THERAPEUTICS

IFNα activates dormant haematopoietic stem cells in vivo

(2009) Marieke A. G. Essers et al.   NATURE

Loss of the Alox5 gene impairs leukemia stem cells and prevents chronic myeloid leukemia

(2009) Yaoyu Chen et al.   NATURE GENETICS

Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib

(2009) Jasmine Foo et al.   PLoS Computational Biology

Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia

(2008) K. Rezvani et al.   BLOOD

Primitive quiescent CD34+ cells in chronic myeloid leukemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib

(2008) A. S. M. Yong et al.   BLOOD

Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression

(2008) F.-X. Mahon et al.   CANCER RESEARCH

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

(2008) Hugues de Lavallade et al.   JOURNAL OF CLINICAL ONCOLOGY

Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase

(2008) Ji Wu et al.   JNCI-Journal of the National Cancer Institute

Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy

(2008) A S M Yong et al.   LEUKEMIA

A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials

(2008) C M Lucas et al.   LEUKEMIA

Multiple sub-microscopic genomic lesions are a universal feature of chronic myeloid leukaemia at diagnosis

(2008) J S Khorashad et al.   LEUKEMIA

CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

(2008) L. Jin et al.   MOLECULAR CANCER THERAPEUTICS

PML targeting eradicates quiescent leukaemia-initiating cells

(2008) Keisuke Ito et al.   NATURE

BCR-ABL-transformed GMP as myeloid leukemic stem cells

(2008) Y. Minami et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA